Literature DB >> 19099443

Luminescent cyclometalated iridium(III) polypyridine indole complexes--synthesis, photophysics, electrochemistry, protein-binding properties, cytotoxicity, and cellular uptake.

Jason Shing-Yip Lau1, Pui-Kei Lee, Keith Hing-Kit Tsang, Cyrus Ho-Cheong Ng, Yun-Wah Lam, Shuk-Han Cheng, Kenneth Kam-Wing Lo.   

Abstract

A series of luminescent cyclometalated iridium(III) polypyridine indole complexes, [Ir(N--C)(2)(N--N)](PF(6)) (HN--C = 2-phenylpyridine (Hppy), N--N = 4-((2-(indol-3-yl)ethyl)aminocarbonyl)-4'-methyl-2,2'-bipyridine (bpy-ind) (1a), N--N = 4-((5-((2-(indol-3-yl)ethyl)aminocarbonyl)pentyl)aminocarbonyl)-4'-methyl-2,2'-bipyridine (bpy-C6-ind) (1b); HN--C = 7,8-benzoquinoline (Hbzq), N--N = bpy-ind (2a), N--N = bpy-C6-ind (2b); and HN--C = 2-phenylquinoline (Hpq), N--N = bpy-ind (3a), N--N = bpy-C6-ind (3b)), have been synthesized, characterized, and their photophysical and electrochemical properties and lipophilicity investigated. Photoexcitation of the complexes in fluid solutions at 298 K and in alcohol glass at 77 K resulted in intense and long-lived luminescence (lambda(em) = 540-616 nm, tau(o) = 0.13-5.15 mus). The emission of the complexes has been assigned to a triplet metal-to-ligand charge-transfer ((3)MLCT) (dpi(Ir) --> pi*(N--N)) excited state, probably with some mixing of triplet intraligand ((3)IL) (pi --> pi*) (pq) character for complexes 3a,b. Electrochemical measurements revealed that all the complexes showed an irreversible indole oxidation wave at ca. +1.1 V versus SCE, a quasi-reversible iridium(IV/III) couple at ca. +1.3 V, and a reversible diimine reduction couple at ca. -1.3 V. The interactions of these complexes with an indole-binding protein, bovine serum albumin (BSA), have been studied by emission titrations, and the K(a) values are on the order of 10(4) M(-1). Additionally, the cytotoxicity of the complexes toward human cervix epithelioid carcinoma (HeLa) cells has been examined by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay. The IC(50) values of the complexes ranged from 1.1 to 6.3 microM, which are significantly smaller than that of cisplatin (30.7 microM) under the same experimental conditions. Furthermore, the cellular uptake of the complexes has been investigated by flow cytometry and laser-scanning confocal microscopy. The microscopy images indicated that complex 3a was localized in the perinuclear region upon interiorization. Temperature-dependence experiments suggested that the internalization of the complex was an energy-requiring process such as endocytosis. This has been confirmed by cellular-uptake experiments involving the luminescent conjugates Ir-BSA and Ir-TF (TF = holo-transferrin), which were prepared by conjugation of the proteins with the complex [Ir(pq)(2)(phen-NCS)](PF(6)) (phen-NCS = 5-isothiocyanato-1,10-phenanthroline).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19099443     DOI: 10.1021/ic801818x

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  11 in total

1.  Red-emitting heteroleptic iridium(III) complexes: photophysical and cell labeling study.

Authors:  Felipe S M Canisares; Alessandra M G Mutti; Edy F Santana; Vytor C Oliveira; Dalita G S M Cavalcante; Aldo E Job; Ana M Pires; Sergio A M Lima
Journal:  Photochem Photobiol Sci       Date:  2022-03-18       Impact factor: 4.328

2.  Cytotoxicity of cyclometalated platinum complexes based on tridentate NCN and CNN-coordinating ligands: remarkable coordination dependence.

Authors:  Dileep A K Vezzu; Qun Lu; Yan-Hua Chen; Shouquan Huo
Journal:  J Inorg Biochem       Date:  2014-02-03       Impact factor: 4.155

3.  Cyclometalated rhodium and iridium complexes with imidazole containing Schiff bases: Synthesis, structure and cellular imaging.

Authors:  Soumik Mandal; Dipak K Poria; Dipravath K Seth; Partho Sarothi Ray; Parna Gupta
Journal:  Polyhedron       Date:  2014-02-10       Impact factor: 3.052

4.  Chiral ruthenium(II) polypyridyl complexes: stabilization of g-quadruplex DNA, inhibition of telomerase activity and cellular uptake.

Authors:  Qianqian Yu; Yanan Liu; Chuan Wang; Dongdong Sun; Xingcheng Yang; Yanyu Liu; Jie Liu
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 5.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

6.  Targeting the endoplasmic reticulum with a membrane-interactive luminescent ruthenium(ii) polypyridyl complex†Electronic supplementary information (ESI) available: Experimental details, characterization of 2 and Fig. S1-S6. See DOI: 10.1039/c3sc51725jClick here for additional data file.

Authors:  Martin R Gill; Denis Cecchin; Michael G Walker; Raminder S Mulla; Giuseppe Battaglia; Carl Smythe; Jim A Thomas
Journal:  Chem Sci       Date:  2013-10-16       Impact factor: 9.825

7.  Targeting cancer cell metabolism with mitochondria-immobilized phosphorescent cyclometalated iridium(iii) complexes.

Authors:  Jian-Jun Cao; Cai-Ping Tan; Mu-He Chen; Na Wu; De-Yang Yao; Xing-Guo Liu; Liang-Nian Ji; Zong-Wan Mao
Journal:  Chem Sci       Date:  2016-08-22       Impact factor: 9.825

8.  Structure-guided discovery of a luminescent theranostic toolkit for living cancer cells and the imaging behavior effect.

Authors:  Chun Wu; Ke-Jia Wu; Jin-Biao Liu; Wanhe Wang; Chung-Hang Leung; Dik-Lung Ma
Journal:  Chem Sci       Date:  2020-09-24       Impact factor: 9.825

Review 9.  Photoactivatable metal complexes: from theory to applications in biotechnology and medicine.

Authors:  Nichola A Smith; Peter J Sadler
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2013-06-17       Impact factor: 4.226

10.  Phosphorescent imaging of living cells using a cyclometalated iridium (III) complex.

Authors:  Dik-Lung Ma; Hai-Jing Zhong; Wai-Chung Fu; Daniel Shiu-Hin Chan; Hiu-Yee Kwan; Wang-Fun Fong; Lai-Hon Chung; Chun-Yuen Wong; Chung-Hang Leung
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.